XML 59 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Strategic Collaborations and Other Significant Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
May 12, 2017
USD ($)
Apr. 25, 2017
USD ($)
Feb. 09, 2017
USD ($)
$ / shares
shares
Jan. 02, 2017
USD ($)
Jan. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
$ / shares
shares
May 31, 2017
USD ($)
$ / shares
shares
Mar. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2017
USD ($)
$ / shares
shares
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
AccountingUnit
$ / shares
shares
Dec. 31, 2016
USD ($)
$ / shares
shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Recognized revenue under license agreement                   $ 87,316,000 $ 41,283,000 $ 28,520,000 $ 20,865,000 $ 1,535,000 $ 177,984,000 $ 1,535,000
Deferred revenue, current           $ 84,910,000       84,910,000       81,968,000 84,910,000 81,968,000
Allocated arrangement consideration                             236,800,000  
Deferred revenue, noncurrent           $ 97,957,000       $ 97,957,000       $ 115,321,000 $ 97,957,000 $ 115,321,000
Common stock shares sold | shares           47,612,619       47,612,619       38,615,709 47,612,619 38,615,709
Common stock, par value | $ / shares           $ 0.00001       $ 0.00001       $ 0.00001 $ 0.00001 $ 0.00001
Proceeds from common stock sold                             $ 373,100,000  
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Upfront cash payment received                             0 $ 40,000,000
Development costs incurred                             19,000,000  
Expected additional development costs                             2,400,000  
Expected reimbursement for development costs                             $ 1,400,000  
Collaboration Agreement, expiration period                             10 years  
Collaboration Agreement, notice period for termination                             12 months  
Number of accounting units | AccountingUnit                             2  
Estimated cost                             $ 21,400,000  
Non-substantive development milestone received                             6,000,000  
Recognized revenue under license agreement                             39,700,000  
Deferred revenue, current           $ 7,500,000       $ 7,500,000         7,500,000  
Accounts receivable           1,300,000       1,300,000         1,300,000  
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue                 $ 245,000,000           265,000,000  
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Upfront                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Upfront cash payment received                 20,000,000           20,000,000  
Incurred clinical and commercial development cost                             20,000,000  
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Development and Regulatory Milestones | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue                             50,000,000  
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Commercial Milestone Payments                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue                 $ 175,000,000              
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Commercial Milestone Payments | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue                             $ 175,000,000  
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Development, Regulatory and Sales Milestones | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Percentage of royalty payments on sales                             20.00%  
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Development, Regulatory and Commercial Events                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue                             $ 225,000,000  
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Development Milestones                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue           6,000,000                 10,000,000  
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Development Milestones | Subsequent Event                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue         $ 4,000,000                      
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Development Milestones | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue                             10,000,000  
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Regulatory Milestone Payments | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Upfront cash payment received                             40,000,000  
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Approval Milestones | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Upfront cash payment received                             40,000,000  
Mitsubishi Tanabe Pharma Corporation | Development and Commercialize Collaboration Agreement | Sales Milestones | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue                             175,000,000  
Mitsubishi Tanabe Pharma Corporation | New Agreement | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Data access fee receivable                     $ 25,000,000          
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize United States Collaboration and License Agreement                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue                             $ 0  
Number of accounting units | AccountingUnit                             3  
Recognized revenue under license agreement                             $ 86,000,000 1,500,000
Deferred revenue, current           45,300,000       45,300,000         45,300,000  
Accounts receivable           17,300,000       17,300,000         $ 17,300,000  
Percentage of market penetration for license agreement                             90.00%  
License agreement, notice period for termination                             12 months  
Cost share payment received                               33,800,000
Estimated cost share payment receivable                             $ 153,600,000  
Allocated arrangement consideration                             312,400,000  
Deferred revenue           99,900,000       99,900,000         99,900,000  
Deferred revenue, noncurrent           54,600,000       54,600,000         54,600,000  
Unbilled accounts receivables           2,000,000       2,000,000         2,000,000  
Cost share costs incurred                             700,000  
Reimbursable by Otsuka                             200,000  
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize United States Collaboration and License Agreement | Global Development Plan                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Reimbursement for Otsuka's share of costs previously incurred               $ 33,800,000                
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize United States Collaboration and License Agreement | Minimum | Global Development Plan                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Collaborative arrangements cost sharing payments       $ 153,600,000                        
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize United States Collaboration and License Agreement | Upfront                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Upfront cash payment received                               $ 125,000,000
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize United States Collaboration and License Agreement | Commercial Milestone Payments | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue                             575,000,000  
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize United States Collaboration and License Agreement | Development Milestones | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Upfront cash payment received                             125,000,000  
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize United States Collaboration and License Agreement | Regulatory Milestone Payments | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue                             65,000,000  
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize United States Collaboration and License Agreement | Up-front, Non-refundable and Non-creditable                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Upfront cash payment received                             125,000,000  
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize International Collaboration and License Agreement                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Recognized revenue under license agreement                             52,300,000  
Deferred revenue, current           32,100,000       32,100,000         32,100,000  
Accounts receivable           15,600,000       15,600,000         15,600,000  
Deferred revenue           70,800,000       70,800,000         70,800,000  
Deferred revenue, noncurrent           38,700,000       38,700,000         38,700,000  
Unbilled accounts receivables           $ 1,700,000       $ 1,700,000         $ 1,700,000  
Milestone or royalty payments received   $ 0                            
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize International Collaboration and License Agreement | Global Development Plan                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Reimbursement for Otsuka's share of costs previously incurred                         200,000      
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize International Collaboration and License Agreement | Minimum | Global Development Plan                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Estimate Subsequent Cost Share Payment Receivable   163,600,000                            
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize International Collaboration and License Agreement | Commercial Milestone Payments | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue   525,000,000                            
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize International Collaboration and License Agreement | Development Milestones | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue   80,000,000                            
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize International Collaboration and License Agreement | Regulatory Milestone Payments | Maximum                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue   52,000,000                            
Otsuka Pharmaceutical Company. Ltd. | Development and Commercialize International Collaboration and License Agreement | Up-front, Non-refundable and Non-creditable                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Upfront cash payment received   $ 73,000,000                            
Janssen Pharmaceutica NV | Development and Commercialize Research and License Agreement                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Collaboration Agreement, expiration period     10 years                          
Collaboration Agreement, notice period for termination     180 days                          
Upfront payment made in cash     $ 1,000,000                          
Warrant to purchase common stock, shares | shares     509,611                          
Aggregate specified development milestone payments payable     $ 16,500,000                          
Specified commercial milestones as well as tiered, escalating royalties payable     $ 215,000,000                          
Johnson & Johnson Innovation | Development and Commercialize Research and License Agreement                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Warrant to purchase common stock, shares | shares     509,611                          
Fair value of warrant               $ 3,400,000         $ 3,400,000      
Exercise price | $ / shares     $ 9.81                          
Vifor (International) Ltd. | License Agreement                                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                
Milestone revenue $ 20,000,000                              
License agreement, notice period for termination 12 months                              
Deferred revenue, noncurrent             $ 4,700,000                  
Common stock shares sold | shares             3,571,429                  
Common stock, par value | $ / shares             $ 0.00001                  
Sale of stock, price per share | $ / shares             $ 14.00                  
Proceeds from common stock sold             $ 50,000,000                  
Premium over the closing stock price of common stock | $ / shares             $ 12.69                  
Premium amount over the closing stock price of common stock             $ 4,700,000